Last updated on September 2018

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Brief description of study

The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in subjects with Acute Kidney Injury (AKI). SBI-101 is a biologic/device combination product designed to regulate inflammation and promote repair of injured tissue using allogeneic human mesenchymal stromal cells. Patients will be randomized to receive one of three treatments, low dose SBI-101, high dose SBI-101, or sham control. SBI-101 will be integrated into the renal replacement circuit and patients will be treated for up to 24 hours.

Clinical Study Identifier: NCT03015623

Contact Investigators or Research Sites near you

Start Over

Brian Miller

Lehigh Valley Hospital
Allentown, PA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.